We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment.
- Authors
Jiang, Yafei; Wang, Jinzeng; Sun, Mengxiong; Zuo, Dongqing; Wang, Hongsheng; Shen, Jiakang; Jiang, Wenyan; Mu, Haoran; Ma, Xiaojun; Yin, Fei; Lin, Jun; Wang, Chongren; Yu, Shuting; Jiang, Lu; Lv, Gang; Liu, Feng; Xue, Linghang; Tian, Kai; Wang, Gangyang; Zhou, Zifei
- Abstract
Osteosarcoma (OS) is a primary malignant bone tumor that most commonly affects children, adolescents, and young adults. Here, we comprehensively analyze genomic, epigenomic and transcriptomic data from 121 OS patients. Somatic mutations are diverse within the cohort, and only TP53 is significantly mutated. Through unsupervised integrative clustering of the multi-omics data, we classify OS into four subtypes with distinct molecular features and clinical prognosis: (1) Immune activated (S-IA), (2) Immune suppressed (S-IS), (3) Homologous recombination deficiency dominant (S-HRD), and (4) MYC driven (S-MD). MYC amplification with HR proficiency tumors is identified with a high oxidative phosphorylation signature resulting in resistance to neoadjuvant chemotherapy. Potential therapeutic targets are identified for each subtype, including platinum-based chemotherapy, immune checkpoint inhibitors, anti-VEGFR, anti-MYC and PARPi-based synthetic lethal strategies. Our comprehensive integrated characterization provides a valuable resource that deepens our understanding of the disease, and may guide future clinical strategies for the precision treatment of OS. Osteosarcoma survival rates have been largely unchanged for several decades, and treatment response is variable. Here, the authors analyzed genomic, transcriptomic and epigenomic data from 121 osteosarcoma patients and identify subtypes related to treatment outcome.
- Subjects
OSTEOSARCOMA; SOMATIC mutation; IMMUNE checkpoint inhibitors; YOUNG adults; PROGNOSIS; IMMUNOCOMPUTERS; PROGRESSION-free survival
- Publication
Nature Communications, 2022, Vol 13, Issue 1, p1
- ISSN
2041-1723
- Publication type
Article
- DOI
10.1038/s41467-022-34689-5